Kuano Funding Round

9/12/2023

Venture Equity

$2,230,000

Seed

The investment will facilitate further validation of Kuano's quantum simulation platform for the design of more effective drug candidates targeting enzymes and continued company growth through strategic partnerships and recruitment.

Private & Independent

Biopharmaceutical

Hauxton House, Mill SciTech Park, Mill Lane
Cambridge, England, CB22 5HX
UK

Undisclosed

Our discovery platform uniquely combines target quantum mapping and AI led chemistry to enable faster development of better drug candidates. Our unique approach tackles common challenges in both AI driven drug design and target driven drug discovery. Quantum Mapping of targets introduces selectivity from the start, producing superior candidates in fewer design rounds. Identifying better starting points for AI-led chemistry eliminates bottlenecks in the hit to candidate optimization phase. Generating better Enzyme Inhibitors by targeting Quantum Transition States. We work with enzyme inhibitors in a unique way, continually developing tools to address the challenges of working with machine learning and quantum simulations in drug discovery. This strategy significantly improves the quality of new drugs being produced, as well as reduces discovery time.